{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31","upperLimit":"69","value":"50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Observed Overall Response Rate = Number of patients who experienced a confirmed CR or PR divided by the number of eligible patients who began treatment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 1000mg/m\\^2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and 1.4mg/m\\^2 eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nEribulin Mesylate: Given IV\n\nGemcitabine Hydrochloride: Given IV","id":"OG000","title":"Treatment (Eribulin Mesylate and Gemcitabine Hydrochloride)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 36 months","title":"Observed Overall Response Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}